Mitigare (Colchicine) Patent Expiration, LOE Window & CMS Spending

Mitigare (Colchicine) by Hikma Pharmaceuticals: FDA Orange Book LOE 2033-08-22, 5 AB generics, $14.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHikma Pharmaceuticals
FDA Application & PathwayN204820 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-08-22
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$14.4M
2024 Medicare Part D Spend$14.0M
2024 Medicaid Spend$372K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.